{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T09:14:15Z","timestamp":1684314855727},"reference-count":0,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[1999,1,1]],"date-time":"1999-01-01T00:00:00Z","timestamp":915148800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Technol Assess Health Care"],"published-print":{"date-parts":[[1999,1]]},"abstract":"<jats:p>Multiple myeloma is a disorder of the bone marrow that is associated with \nbone pain and osteolytic lesions. These complications can lead to the \ndevelopment of pathologic fractures and severe patient morbidity. However, the \nresults of a recent randomized trial in patients with multiple myeloma \ndemonstrated that single 90 mg monthly doses of pamidronate as an adjunct to \nchemotherapy reduced the incidence of skeletal-related events and improved \npatients' quality of life. A cost-benefit analysis using an <jats:italic>ex-ante \ninsurance<\/jats:italic> willingness-to-pay (WTP) approach was conducted from a Canadian \nsocietal perspective to estimate the net cost or benefit of prophylactic \npamidronate therapy for patients with multiple myeloma. This included direct \ncosts for drug administration and hospital savings secondary to avoiding \nskeletal-related events. One hundred Canadian taxpayers were then interviewed \nto ascertain their maximum WTP for the benefits of pamidronate. The WTP survey \ninstrument was simple to administer and easily understood by participants. \nRespondents stated that they would be willing to pay an average of Can $3,364 \n(95% CI: $2,096, $4,632) as an income tax increase to be paid over their \nlifetime for the value offered by the product. The benefit was then subtracted \nfrom the overall cost of nine monthly doses of pamidronate ($4,153) producing \na net societal cost of $789 per patient (95% CI: (\u2212$479, $2,057). The \nadministration of monthly pamidronate therapy in multiple myeloma patients \nproduces a situation of cost neutrality (societal benefits = costs). \nAdditional clinical trials to identify high-risk patient subgroups that would \nmost benefit from the drug are needed.<\/jats:p>","DOI":"10.1017\/s0266462399015202","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T13:36:57Z","timestamp":1027777017000},"page":"108-122","source":"Crossref","is-referenced-by-count":7,"title":["PAMIDRONATE FOR THE PREVENTION OF SKELETAL- RELATED EVENTS IN MULTIPLE \nMYELOMA"],"prefix":"10.1017","volume":"15","author":[{"given":"George","family":"Dranitsaris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[1999,1,1]]},"container-title":["International Journal of Technology Assessment in Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0266462399015202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T19:21:29Z","timestamp":1557516089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0266462399015202\/type\/journal_article"}},"subtitle":["What Does the Public Think It Is Worth?"],"short-title":[],"issued":{"date-parts":[[1999,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,1]]}},"alternative-id":["S0266462399015202"],"URL":"https:\/\/doi.org\/10.1017\/s0266462399015202","relation":{},"ISSN":["0266-4623","1471-6348"],"issn-type":[{"value":"0266-4623","type":"print"},{"value":"1471-6348","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,1]]}}}